Literature DB >> 31675126

Breast cancer incidence and mortality before and after implementation of the German mammography screening program.

Alexander Katalinic1,2, Nora Eisemann1, Klaus Kraywinkel3, Maria R Noftz1, Joachim Hübner1.   

Abstract

Effective population-based mammography screening should impact breast cancer (BC) incidence, age and stage-specific incidence and BC mortality. We aim to investigate such effects in a time period of 10 years after implementation of the German mammography screening program. Data on 323,719 breast cancer patients from 2003 to 2014 for defined regions covering a population of 30 million inhabitants and official mortality data from 1998 to 2016 for almost the whole of Germany were used. We compared incidence and mortality rates for the prescreening time period (2003/2004) and the latest available data (2013/2014 and 2015/2016, respectively) and performed trend analyses using joinpoint regression models. In the screening exposed age groups (50-59 and 60-69 years), BC incidence showed a typical prevalence peak with the introduction of the mammography screening, mainly driven by an increase of early-stage BC. For Stage III and IV BC incidence in 2013/2014 was 24.2 and 23.0% (age group 50-59 years) and 28.3 and 24.2% (age group 60-69 years) lower than in the prescreening period. From 2003/2004 to 2015/2016 BC mortality decreased by 25.8 and 21.2%, respectively. As corresponding trends in nonexposed age groups were distinctly unfavorable, the reduction of late-stage BC incidence and BC mortality in the screening exposed age groups in Germany is most likely to be attributed to the introduction of the national mammography screening program. These positive effects are bought at the cost of a moderate occurrence of overdiagnosis, especially by a sharp increase of in situ cancers.
© 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.

Entities:  

Keywords:  breast cancer; incidence; mammography screening; mortality

Year:  2019        PMID: 31675126     DOI: 10.1002/ijc.32767

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  Optimized process quality in certified breast centers through adherence to stringent diagnostic and therapeutic algorithms effects of structural as well as socio-demographic factors on start of therapy.

Authors:  Saskia-Laureen Herbert; Paula Hirzle; Catharina Bartmann; Tanja Schlaiß; Matthias Kiesel; Carolin Curtaz; Sanja Löb; Achim Wöckel; Joachim Diessner
Journal:  Arch Gynecol Obstet       Date:  2022-08-05       Impact factor: 2.493

2.  Effect of postoperative chemotherapy on blood glucose and lipid metabolism in patients with invasive breast cancer.

Authors:  Aiying Qi; Yanping Li; Susu Yan; Huiying Sun; Meiling Zhao; Yuhui Chen
Journal:  Gland Surg       Date:  2021-04

Review 3.  [Systematic and quality-assured early diagnosis of sporadic breast cancer : Update on screening effects and scientific studies].

Authors:  Walter Heindel; Karin Bock; Gerold Hecht; Sylvia Heywang-Köbrunner; Vanessa Kääb-Sanyal; Katja Siegmann-Luz; Stefanie Weigel
Journal:  Radiologe       Date:  2021-01-25       Impact factor: 0.635

4.  Influence of Breast Density on Patient's Compliance during Ultrasound Examination: Conventional Handheld Breast Ultrasound Compared to Automated Breast Ultrasound.

Authors:  Sara De Giorgis; Nicole Brunetti; Jeries Zawaideh; Federica Rossi; Massimo Calabrese; Alberto Stefano Tagliafico
Journal:  J Med Ultrasound       Date:  2020-06-04

5.  Cancer treatment regimens and their impact on the patient-reported outcome measures health-related quality of life and perceived cognitive function.

Authors:  Niklas Paul Grusdat; Alexander Stäuber; Marion Tolkmitt; Jens Schnabel; Birgit Schubotz; Peter Richard Wright; Marc Heydenreich; Dirk-Henrik Zermann; Henry Schulz
Journal:  J Patient Rep Outcomes       Date:  2022-02-21

6.  Epidemiological and sociodemographic transitions of female breast cancer incidence, death, case fatality and DALYs in 21 world regions and globally, from 1990 to 2017: An Age-Period-Cohort Analysis.

Authors:  Sumaira Mubarik; Yong Yu; Fang Wang; Saima Shakil Malik; Xiaoxue Liu; Muhammad Fawad; Fang Shi; Chuanhua Yu
Journal:  J Adv Res       Date:  2021-08-02       Impact factor: 12.822

7.  Global Burden of Female Breast Cancer: Age-Period-Cohort Analysis of Incidence Trends From 1990 to 2019 and Forecasts for 2035.

Authors:  Yizhen Li; Jinxin Zheng; Yujiao Deng; Xinyue Deng; Weiyang Lou; Bajin Wei; Dong Xiang; Jingjing Hu; Yi Zheng; Peng Xu; Jia Yao; Zhen Zhai; Linghui Zhou; Si Yang; Ying Wu; Huafeng Kang; Zhijun Dai
Journal:  Front Oncol       Date:  2022-06-09       Impact factor: 5.738

8.  The Lack of Evidence for an Association between Cancer Biomarker Conversion Patterns and CTC-Status in Patients with Metastatic Breast Cancer.

Authors:  Stefan Stefanovic; Thomas M Deutsch; Sabine Riethdorf; Chiara Fischer; Andreas Hartkopf; Peter Sinn; Manuel Feisst; Klaus Pantel; Michael Golatta; Sara Y Brucker; Marc Sütterlin; Andreas Schneeweiss; Markus Wallwiener
Journal:  Int J Mol Sci       Date:  2020-03-21       Impact factor: 5.923

9.  You Get What You Pay For: Breast MRI Screening of Women With Dense Breasts Is Cost-effective.

Authors:  Christiane K Kuhl; Pascal Baltzer
Journal:  J Natl Cancer Inst       Date:  2021-11-02       Impact factor: 13.506

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.